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Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when
treated with palliative intent platinum-based chemotherapy alone. Recent advances
in imaging and therapeutic strategy have identified a subset of patients with limited
metastases who may benefit from early local ablative therapy with either surgery
or radiotherapy, in addition to standard treatment. Stereotactic body radiotherapy
(SBRT) is increasingly used in the treatment of extra-cranial oligometastatic NSCLC
(OM-NSCLC) due its non-invasive conduct and ability to deliver high doses. Clinical
evidence supporting the use of SBRT in OM-NSCLC is emerging and consistently
demonstrates significant benefit in local control and progression-free survival. Here, we
discuss the definition of oligometastases (OM), review current available data on SBRT
treatment in extra-cranial OM-NSCLC including evidence for site-specific SBRT in lung,
liver, and adrenal metastases.
Keywords: stereotactic body radiotherapy, non-small cell lung cancer, lung cancer, oligometastases,
oligometastatic disease
INTRODUCTION
Lung cancer continues to be the leading cause of cancer death inmany countries (1). Unfortunately,
about two-thirds of non-small cell lung cancer (NSCLC) patients present with metastatic disease
(Stage IV) at diagnosis and are considered incurable (2). For these patients, systemic therapy
continues to be the mainstay of treatment. However, with conventional chemotherapy alone, the
median survival hovers around 10 months, and long-term survival is unlikely (3). There can be
considerable heterogeneity within stage IV classification, with a sub-group of stage IV patients
(especially those with low-volume metastatic disease) having prolonged survival. This led to the
8th edition of American Joint Committee on Cancer (AJCC) to further categorize stage IV. In
particular, patients with a single extra-thoracic metastasis was classified as M1b (Stage IVA), as
opposed to patients with multiple lesions in one or multiple organs (M1c, Stage IVB) (4). Precisely
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classifying these patients improves the prognostic value and in
doing so, will help guide treatment; in particular, identifying
patients with OM-NSCLC who may warrant aggressive
management of the primary tumor, as well as the metastatic sites.
The term “oligometastatic” disease has been used commonly
(and sometimes loosely) in the cancer literature ever since 1995.
Hellman and Weichselbaum were the first to introduce this
concept of OM disease, which represented an intermediate state
in the spectrum between locally confined and widely metastatic
cancer (5, 6). They proposed that the process of metastatic
disease occurs in a step-wise manner, and patients with limited
disease should be managed aggressively. In more recent years,
advances in systemic/targeted therapy may render a greater
proportion of patients with upfront widely metastatic disease to
a state of limited volume metastatic disease. In these patients,
aggressive management of drug-resistant clones may improve
cancer outcomes.
Surgical metastasectomy was initially the only way to
radically manage these patients (7). With the advent of intra-
cranial stereotactic radiosurgery, high doses of ablative radiation
delivered over a limited number of fractions were seen to be
as effective as surgical resection (8, 9). Advances in imaging,
treatment delivery and patient immobilization now allow us
to perform ablative radiation to extra-cranial sites in the form
of stereotactic body radiotherapy (SBRT) (10). SBRT has an
advantage over surgical metastasectomy in that it is non-invasive,
well-tolerated and has fewer interruptions to systemic therapy.
In this mini-review, we will discuss the definitions of OM
disease (in the context of NSCLC), patient selection, prognostic
factors as well as completed and ongoing trials to support the use
of SBRT for OM-NSCLC.
INCIDENCE AND DEFINITION OF
OLIGOMETASTATIC CANCER
To date, there is no universal definition of what constitutes OM
with regards to the number of lesions or sites involved. The most
accepted number of metastatic lesions is considered to be 5 or less
(with up to 3 metastases in an organ) (11–14).
As definitions of OM vary from study to study, it is hard
to estimate the exact incidence of OM in NSCLC at diagnosis.
Moreover, the routine use of staging FDG/PET-CT scan and
MRI brain imaging may increase the incidence of OM, due to
increased sensitivity compared to older imaging modalities. The
International Association for the Study of Lung Cancer (IASLC)
Lung Cancer staging project found that 225 out of 1,025 (22%)
patients had synchronous single metastatic lesion at diagnosis;
this group of patients had a better prognosis compared to patients
with metastases in multiple organs (15). In another study by
Parikh et al., 26% of patients had 5 or fewer metastases at
diagnosis, and half of these patients only had 1 metastases (16).
In terms of classifying oligometastatic cancer, there are three
possible scenarios:
1) Synchronous oligometastatic disease: Patients who present
with up to 5 metastatic lesions (in one or a few organs) at first
or within 6 months of diagnosis. These typically occur in the
brain, lung parenchyma, liver or bone (15).
2) Oligo-residual (or oligo-persistent) disease: Widely metastatic
disease (>5) at diagnosis, which has responded well to
systemic therapy (i.e., complete response), with the remaining
lesions (up to 5) amenable to radical local therapy (e.g.,
surgery, SBRT, RFA) (17).
3) Metachronous (or oligo-recurrence): Patients who had been
treated with curative intent, and then present with limited
sites of metastatic disease (up to 5) after an interval of stable
disease (18).
As oligoprogression is a biologically distinct entity whereby
patients with upfront widespread metastases progress, in a
limited number of sites, after initially achieving stable disease
or partial response, we have not included it in this definition.
It is possible that patients with oligoprogression have a worse
prognosis compared to the above scenarios.
CHOICE OF LOCAL THERAPY: BETWEEN
SURGERY, SBRT, AND RADIOFREQUENCY
ABLATION
Selecting the most effective method for local treatment of
oligometastases requires thoughtful considerations. Patient-
related factors (e.g., age, performance status and organ function,
patient preferences), tumor-related factors (e.g., location, size,
proximity to vessels or nearby critical organs) and treatment-
related factors (e.g., availability of expertise, cost, and waiting list)
have to be taken into account.
In the latest National Comprehensive Cancer Network
(NCCN) guideline for stage IVA NSCLC, definitive RT to
OM, with particular mention of SBRT, is recommended as an
appropriate option in suitable patients with good performance
status provided it can be delivered safely (19). This reflects
a growing trend and clinical evidence supporting the use of
SBRT for OM. A survey of 1,007 radiation oncologists from 43
countries published by Lewis et al. in 2017 reported that 83% have
been using SBRT for extracranial OM since 2005 (with over 30%
since 2010) with treatment response and durability as the main
reason for choosing SBRT (20). The survey reported the most
common treated organs were lung, liver, and spine (90, 75, and
70%, respectively).
There are no head-to-head studies comparing surgery, SBRT,
and RFA. In liver metastases, SBRT is superior to RFA in treating
larger lesions >3 cm, or for lesions near blood vessels where
there can be a heat-sink effect with RFA (21, 22). Widder et al.
retrospectively analyzed 110 patients with pulmonary OM who
were offered surgery as first line treatment for OM and SBRT
if they were unsuitable for surgery (23). Although SBRT was
offered as an alternative option, OS and local control rates were
comparable between the two groups. As such, due to its non-
invasive conduct and ability to deliver highly conformal high
dose radiotherapy, SBRT has been increasingly used to target
OM lesions especially for patients with technically unresectable
lesions or those who are unfit for surgery.
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PROGNOSTIC FACTORS AND PATIENT
SELECTION
Patient selection is not only important to ensure the safe
delivery of SBRT but also has prognostic significance (24). Several
previous studies have attempted to streamline patient selection
through identifying prognostic factors.
In a retrospective cohort study involving 186 patients, ECOG
performance status >2, higher nodal-status (N2-3), squamous
histology and metastases to multiple organs were associated with
a worse prognosis (16). Ashworth and colleagues performed an
individual patient meta-analysis using data from 757 patients
treated curatively at the primary site, and with up to 5 metastatic
lesions, treated radically with local therapies such as surgical
resection, SBRT, high-dose radical RT (25). Surgery was the
most commonly used treatment for the primary site (83.9%)
and the metastatic sites (62.3%). The median survival of these
patients was 26 months, and approximately a third survived
5 years. Key findings from this study are that patients with
metachronous metastases, lower N status and adenocarcinoma
histology were predicted to have longer OS. The authors
proposed stratifying patients into three risk groups: low-risk
(metachronous metastases, 5-year OS 47.8%), intermediate-risk
(synchronous metastases with N0 disease, 5-year OS 36.2%), and
high-risk (synchronous metastases with N1/N2 disease, 5-year
OS 13.8%) (25), however this classification scheme is yet to be
formally validated in clinical trials.
The number (and possibly volume) of metastatic sites has
also been shown to be a potential prognostic factor. In a SWOG
study by Albain et al., involving 2,531 patients with advanced
NSCLC, median survival was highest in patients with a single
lesion (8.7months), compared to patients withmultiple lesions in
one organ (6.2 months) and multiple lesions in multiple organs
(5.1 months) (26). Similarly in the subgroup analysis of RTOG
9508 trial, which allowed up to 3 brain metastases, survival
improvement (with the addition of stereotactic radiosurgery) was
only found in patients with a single lesion compared to 2–3
lesions (27). Looking at the use of SBRT in particular, patients
with up to 3 lesions had a better OS compared to patients with
4–5 lesions (2-year OS 60.3 vs. 21.9%). However, it must be noted
that only 11 of 61 patients had NSCLC (28).
SBRT TO EXTRA-CRANIAL SITES
COMMONLY SEEN WITH
OLIGOMETASTATIC NSCLC (LUNG, LIVER,
ADRENAL)
A) Lung: Prior studies on SBRT in primary NSCLC have
reported local control rate comparable to surgery when the
biologically effective dose (BED) of SBRT was at least 100Gy
(29–32). De Rose et al. reviewed 60 patients treated with
SBRT for lung metastases in NSCLC with 60Gy in 3 fractions
to peripheral lesions<2 cm, 48Gy in 4 fractions to peripheral
lesions between 2 and 5 cm, and 60Gy in 8 fractions to central
lesions (30). All patients received a BED > 100Gy resulting
in a 2-year local control rate of 88.9% and 1- and 2-year OS of
94.5 and 74.6%, respectively. Laterality of metastatic disease
does not seem to influence survival outcomes. For example,
the survival was not significantly different between ipsilateral
(T4, M0) vs. contralateral (M1a) surgical metastasectomy in
43 patients with NSCLC (27 vs. 43%) (33). Notably, none
of the patients with mediastinal node involvement achieved
long-term survival. More accurate staging with FDG-PET
scan prior to SBRT significantly improved 1- and 2-year
OS (82.7 vs. 72.8% and 64.8 vs. 52.6%, respectively, P =
0.012) (34). Pre-treatment performance status, maximum
metastasis diameter, primary tumor histology, number of
metastases, and time interval between primary tumor
diagnosis and SBRT treatment significantly influenced OS
(35). SBRT to the lung is generally well-tolerated with most
patients experiencing grade 1–2 late pulmonary toxicity and
grade 3 pulmonary toxicity in the minority (30, 31) and
the BED at the planning target volume (PTV) isocenter was
the only factor reported to influence toxicity in a database
analysis of 700 patients treated with SBRT for oligometastatic
lung disease (35).
B) Liver: Ahmed et al. evaluated the radiosensitivity of
liver metastases from different primary histology using a
multigene expression index for tumor radiosensitivity (RSI)
(36). They suggested that NSCLC has an intermediate radio-
sensitivity (median RSI 0.31). Majority of the series reporting
outcome of SBRT to liver metastases involve colorectal
primaries. In the context of NSCLC, the presence of liver
metastases has been associated with a worse prognosis
compared to metastases to other sites in NSCLC (37, 38).
Milano et al. evaluated the use of 50Gy in 5 fractions
for SBRT to treat hepatic metastases (∼20% lung primary)
and reported a 2-year local control rate of 67% (39).
Rusthoven et al. (also ∼20% lung primary) reported a
higher 2-year local control rate of 92% with SBRT regimen
of 30–60Gy in 3 fractions (40). In a pooled analysis
involving 474 patients with 623 liver metastases (with mainly
colorectal and breast primary), increasing the maximum
isocenter BED to >150Gy EQD2Gy, increased 1- and 2-year
control rate of treated lesions from 77–83% and 64–70%,
respectively (41).
C) Adrenal: SBRT to adrenal metastases in OM-NSCLC was
specifically evaluated in a study by Celik et al. whereby 15
patients received 42Gy in 6 fractions of CyberKnife R© SBRT
(42). One and two-year local control rates were 60 and 46.6%,
respectively. Patient with metachronous metastases had a
more favorable 2-year overall survival of 91.2% compared
to 42.8% in patients with synchronous adrenal metastases.
Holy et al. reported an overall median PFS of 4.2 months
in their group of 18 patients with adrenal metastases from
NSCLC treated with SBRT (range 20–40Gy in 5 fractions)
(43). Of these, 13 patients with isolated adrenal metastasis
had longer median PFS of 12 months, local control rate of
77% (median follow-up: 21 months), and median OS of 23
months. SBRT for adrenal metastases is reasonably tolerated
with previous studies reporting grade 1–2 toxicities including
gastrointestinal toxicity, fatigue, rarely duodenal ulcers, and
possibly late adrenal insufficiency (42, 44, 45).
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TABLE 1 | Selected studies of SBRT treatment in oligometastatic NSCLC.
References Year Patients
(n)
Site of
oligo-met
N Dose
(Gy/fraction)
Systemic
therapy
Median
follow-up
(months)
Median PFS
(months)
Median OS
(months)
RETROSPECTIVE STUDIES
Inoue et al. (47) 2010 41* Brain, lung,
adrenal
<5 48/8 (adrenal)
35–60/4–8 (lung)
NA 20 3-year PFS
20%
24
Holy et al. (43) 2011 18 Adrenal NA 20–40/5 Various 21 4.2 (all)
12 (1 met)
23 (1 met)
Hasselle et al. (48) 2012 25 Multiple <5 24–70/3–20 Chemo or
targeted
therapy
14 7.6 22.7
De Rose et al. (30) 2016 60 Lung <5 48–60/3–8 Chemo 28 32.2
(actuarial)
32.1 (actuarial)
Celik et al. (42) 2017 15 Adrenal <5 42/6 Chemo 24 10.5 2-year OS 46.6%
SINGLE ARM PROSPECTIVE TRIALS
Salama et al. (28) 2012 61* Multiple <5 24–48/3 Chemo 20.9 2-year PFS
22%
2-year OS 56.7%
De Ruysscher
et al. (49)
2012 40 Multiple <5 54/3** Chemo 27.7 12.1 13.5
Collen et al. (50) 2014 26 Multiple <5 50/10 Chemo 16.4 11.2 23
RANDOMIZED PHASE II TRIALS
Gomez et al. (12) 2016 49 Multiple <3 NR Chemo 12.4 14.2 vs. 4.4 41.2 vs. 17
Iyengar et al. (11) 2018 29 Multiple <5 21–37.5/1–5 Chemo 9.6 9.7 vs. 3.5 Not reached vs. 17
Palma et al. (13) 2019 99 Multiple <5 35–60/3–8 Chemo 25 12 vs. 6 41 vs. 28
N, number of oligometastatic lesions per patient; OS, overall survival; NR, data not reported; PFS, progression free survival.
*Various primary histology including NSCLC. **Only one patient received SBRT.
SUMMARY OF EVIDENCE SUPPORTING
SBRT IN OM-NSCLC
A retrospective analysis of patterns-of failure after first-line
systemic therapy in 387 patients with NSCLC reported local
progression as the predominant pattern-of failure and suggested
that local consolidative therapy with SBRT to known sites
of disease following systemic therapy to prolong the time
to first progression (46). Since then, trials of patients with
limited metastatic NSCLC treated with SBRT have demonstrated
significant survival benefit in both first and second line
settings (Table 1).
Single Arm Prospective Trials
1) Collen et al. reported on 26 patients with synchronous
OM-NSCLC patients with up to 5 metastases treated with
SBRT (50Gy in 10 fractions) (50). Notably, patients with
uncontrolled primary tumors were eligible. The primary
endpoint was complete metabolic response (CMR) on PET
(3 months post-SBRT). Seventeen patients underwent SBRT
after upfront chemotherapy, and the remaining underwent
SBRT (to all sites) as primary treatment. Sixty percent of
patients achieved metabolic response, with half of reaching
CMR. The median PFS was 11.2 months, and median OS
23 months.
2) De Ruysscher et al. included 40 patients with synchronous
OM-NSCLC (≤5 lesions) who were amenable for radical
therapy to all tumor sites including the primary (surgery,
stereotactic radiosurgery, fractionated RT to a dose of 60Gy,
and one patient received treatment with 54Gy in 3 fractions
of SBRT) (49). The vast majority had a single metastatic
focus, and were treated with upfront chemotherapy, and
approximately half had brain metastases. They report a
median PFS of 12.1 months, and OS of 13.5 months. The
inferior results compared to the Collen study may be related
the larger proportion of patients with brain metastases in this
cohort, or the use of conventionally fractionated RT.
3) Bauml et al. recently published their single-arm Phase II trial
comprising of 51 patients with ≤4 lesions who completed
locally ablative therapy to all sites, following which they
were given pembrolizumab. They reported a median PFS of
19.1 months and 1-year OS of 90.9%. This is notably much
improved compared to historical controls (51).
Randomized Phase II Trials
1) Iyengar et al. then conducted a randomized phase II trial for
29 patients with NSCLC and up to 5 OM lesions. NSCLC
who had achieved partial response or stable disease to first-
line chemotherapy (11). EGFR/ALK positive patients were
excluded. They were randomized to SBRT + maintenance
chemotherapy vs. maintenance chemotherapy alone. The trial
was stopped early due to significant improvements with the
addition of SBRT (PFS 9.7 vs. 3.5months, P= 0.01). Toxicities
were similar in both arms.
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2) Gomez et al. conducted a multi-center Phase II randomized
study in 49 patients with up to 3 OM NSCLC with no
progression for at least 3 months post 1st line chemotherapy
(12, 52). Eighty-four percent were EGFR/ALK negative.
Patients were assigned to local therapy (surgery or radical
RT) vs. maintenance chemotherapy or observation. Like the
previous trial, this study was stopped early due to significant
improvements in PFS in the local therapy arm (PFS 14.2 vs. 4.4
months, P = 0.022). OS was also significantly improved (OS
41.2 vs. 17 months, P = 0.017). There are two observations
from this study. Firstly, the OS benefit was seen despite
patients crossing-over frommaintenance/observation to local
therapy, suggesting earlier local therapy to be superior to
local therapy on progression. Secondly, none of the patients
suffered from Grade 3 toxicity.
3) Palma et al. conducted the international SABR-COMET Phase
II trial including 99 patients with up to 5 OM lesions from a
variety of primary histological types (20% lung primary) (13).
Patients were randomized to SBRT to all sites vs. palliative
standard of care alone. The primary endpoint, which was OS,
TABLE 2 | Selected ongoing trials of SBRT treatment in oligometastatic NSCLC.
Title Patients Study design Estimated
completion
Stereotactic Ablative Radiotherapy for Oligometastatic
Non-small Cell Lung Cancer (SARON). A Randomized
Phase III Trial. (53)
Institution: University College London
ClinicalTrials.gov identifier: NCT02417662
340 Phase 3 multi-center: chemotherapy alone (standard platinum
based doublet chemotherapy or chemotherapy + radical
radiotherapy (conventional RT and SABR)
Primary histology: all NSCLC
1–3 oligometastatic lesions
Primary outcome measure: OS
August 2022
Maintenance Systemic Therapy vs. Local Consolidative
Therapy (LCT) Plus Maintenance Systemic Therapy for
Limited Metastatic Non-small Cell Lung Cancer
(NSCLC): A Randomized Phase II/III Trial (NRG LU-002)
Institution: NRG Oncology
ClinicalTrials.gov identifier: NCT03137771
300 Phase 2/3 multi-center: maintenance chemotherapy or SBRT +
maintenance chemotherapy
Primary histology: all NSCLC
1–3 oligometastatic lesions
Primary outcome measure: PFS
April 2022
Randomized Phase III Trial of Local Consolidation
Therapy (LCT) After Nivolumab and Ipilimumab for
Immunotherapy-Naive Patients With Metastatic
Non-small Cell Lung Cancer (LONESTAR) -Strategic
Alliance: BMS
Institution: M.D. Anderson Cancer Center
ClinicalTrials.gov identifier: NCT03391869
270 Phase 3 multi-center: systemic treatment only with nivolumab and
ipilimumab or induction nivolumab and ipilimumab followed by
local consolidative therapy with surgery and/or radiotherapy
Primary histology: all NSCLC
>1 oligometastatic lesions
Primary outcome: OS
December 2022
A Randomized Trial of Conventional Care vs.
Radioablation (Stereotactic Body Radiotherapy) for
Extracranial Oligometastases (CORE)
Institution: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov identifier: NCT02759783
245 Phase 2/3 multi-center: standard of care or standard of care +
SBRT
Primary histology: breast, prostate, or NSCLC
1–3 oligometastatic lesions
Primary outcome measure: PFS
October 2024
A Randomized Phase III Trial of Stereotactic Ablative
Radiotherapy for the Comprehensive Treatment of 4–10
Oligometastatic Tumors (SABR-COMET 10)
Institution: Lawson Health Research Institute
ClinicalTrials.gov identifier: NCT03721341
159 Phase 3 multi-center: stereotactic ablative radiotherapy, plus
standard of care treatment: chemotherapy, immunotherapy,
hormones, or observation given at the discretion of the treating
oncologist
Various histology including NSCLC
4 to 10 oligometastatic lesions
Primary outcome: OS
January 2029
Randomized Phase II Trial of Local Consolidation
Therapy (LCT) After Osimertinib for Patients With EGFR
Mutant Metastatic Non-small Cell Lung Cancer (NSCLC)
(NORTHSTAR)
Institution: M.D. Anderson Cancer Center
ClinicalTrials.gov identifier: NCT03410043
143 Phase 2 multi-center: osimertinib followed by local consolidative
therapy with surgery and/or radiotherapy or maintenance
osimertinib alone
Primary histology: NSCLC
>1 oligometastatic lesion
Primary outcome: PFS
January 2023
A Multicentre Single Arm Phase II Trial Assessing the
Efficacy of Immunotherapy, Chemotherapy and
Stereotactic Radiotherapy to Metastases Followed by
Definitive Surgery or Radiotherapy to the Primary Tumor,
in Patients With Synchronous
Oligo-metastatic NSCLC
Institution: European Thoracic Oncology Platform
ClinicalTrials.gov identifier: NCT03965468
47 Phase 2 multi-center: durvalumab, carboplatin/paclitaxel
chemotherapy, followed by SBRT to all oligometastases.
Restaging at 3 months Definitive local treatment with surgical
resection of primary tumor or RT 60–66Gy to the primary tumor if
no disease progression.
1–3 oligometastatic lesions
Primary outcome: PFS
December 2021
RT, radiotherapy; SBRT, stereotactic body radiation therapy; SABR, stereotactic ablative radiotherapy; OS, overall survival; PFS, progression free survival.
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was prolonged with addition of SBRT (41 vs. 28 months, P =
0.09). Unfortunately, there were significantly more toxicity in
the SBRT arm (29 vs. 9%) with treatment-related death (Grade
5) being experienced by three patients (4.5%).
Phase III Trials
No Phase III trial has reported the benefit of SBRT in OM-
NSCLC. In view of the convincing Phase II data, there are
multiple ongoing Phase III trials which are eagerly awaited. These
trials are summarized in Table 2.
FUTURE DIRECTION AND UNANSWERED
QUESTIONS
Considerable progress has been made in the realm of OM-
NSCLC. Improvements in survival stem partly from more
effective systemic therapy, but also aggressive consolidation
therapies (surgery, radiation) in patients with a favorable disease
biology. Although the results from randomized Phase II data
are exciting, adequately powered Phase III trials with clear
inclusion/exclusion criteria (e.g., synchronous, metachronous,
oligorecurrence) and appropriate primary endpoints are much
awaited to change practice. The upper limit of the number of
acceptable OM lesions were set rather arbitrarily. It remains
unclear if we should limit this to 3, 5 or 10 (54). As such,
two randomized Phase III trials are being planned. SABR-
COMET 3 (NCT03862911) for 1–3 lesions, and SABR-COMET
10 (NCT03721341), for 4–10 lesions. Moreover, most of the
prospective OM-NSCLC trials have been performed in the
Caucasian population where EGFR/ALK driver mutations are
known to be much lower than in Asian countries. There remain
many unanswered questions about how best to manage these
patients including clinical uncertainty if these principles can be
extrapolated to populations with higher prevalence of driver
mutations. Lastly, most of the studies were conducted prior to the
use of immunotherapy. Therefore, the role of SBRT in the context
of immunotherapy is uncertain.
CONCLUSION
Stage IV NSCLC represents a heterogenous group of patients
with an overall poor outcome. However, a sub-group of patients
with limited metastatic disease may achieve long-term survival
with effective systemic therapy and aggressive local therapy.
SBRT is a good option to obtain durable local control, and
possibly prolong survival for these patients. At the same time,
SBRT can be a double-edged sword, with toxicities in a minority
of patients. As always, appropriate patient selection remains
paramount, and ongoing Phase III trials will provide clarity.
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